Clinical trials: Potassium Depletion
Primary Hyperaldosteronism
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
- Trial name
- NCT00732771
- Testing
- LCI699
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Novartis
Arterial Hypertension, Diabetes
Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes.
- Conditions
- Arterial Hypertension, Diabetes, Hypokalemia, Hyponatremia
- Trial name
- CHAMP (NCT02709031)
- Testing
- Cicletanine + magnesium, Cicletanine
- Volunteers
- 24 people
- Sponsor
- Navitas Pharma
Hyperkalemia, Hypokalemia
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
China National Heart Failure Registration Study (CN-HF) is a nationwide, hospital-based, multicentre, prospective registry study sponsored by Ministry of Science and Technology of the People's Republic of China.
- Conditions
- Hyperkalemia, Hypokalemia, Heart Failure
- Trial name
- SPLENDID (NCT05184998)
- Where
- China
- Volunteers
- 6,950 people
- Sponsor
- AstraZeneca